Liver transplantation and transthyretin amyloidosis

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Liver transplantation as a specific treatment of transthyretin amyloidosis was first performed in 1990. The rationale for this treatment was that removal of the source (liver) of the amyloid precursor protein (mutated transthyretin) would stop progression of the disease. Indeed, after orthotopic liver transplantation (OLT), mutant transthyretin (TTR) is rapidly cleared from circulation. In the last 20 years, >2000 familial amyloidotic polyneuropathy (FAP) patients have received liver transplants. For these patients, prospective monitoring has shown prolongation of life compared with FAP patients who have not undergone liver transplantation. The most favorable results have been for FAP patients with the Val30Met TTR mutation. Less favorable results have been seen for patients with other TTR mutations where progression of amyloid tissue deposition has been documented as the result of amyloid fibril formation from normal (wild-type) TTR. Although it is obvious that OLT has benefited many FAP patients, there remains a need for further therapies.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalMuscle and Nerve
Volume47
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Prealbumin
Liver Transplantation
Polyneuropathies
Amyloid
Life Support Care
Mutation
Amyloid beta-Protein Precursor
Liver
Physiologic Monitoring
Disease Progression
Therapeutics
Amyloidosis, Hereditary, Transthyretin-Related
Transplants

Keywords

  • Amyloidosis
  • Familial amyloidotic polyneuropathy
  • FAP
  • Liver transplant
  • Transthyretin
  • TTR

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Liver transplantation and transthyretin amyloidosis. / Benson, Merrill.

In: Muscle and Nerve, Vol. 47, No. 2, 02.2013, p. 157-162.

Research output: Contribution to journalArticle

@article{3a56b6731f3840a6b7dab527344f0a2d,
title = "Liver transplantation and transthyretin amyloidosis",
abstract = "Liver transplantation as a specific treatment of transthyretin amyloidosis was first performed in 1990. The rationale for this treatment was that removal of the source (liver) of the amyloid precursor protein (mutated transthyretin) would stop progression of the disease. Indeed, after orthotopic liver transplantation (OLT), mutant transthyretin (TTR) is rapidly cleared from circulation. In the last 20 years, >2000 familial amyloidotic polyneuropathy (FAP) patients have received liver transplants. For these patients, prospective monitoring has shown prolongation of life compared with FAP patients who have not undergone liver transplantation. The most favorable results have been for FAP patients with the Val30Met TTR mutation. Less favorable results have been seen for patients with other TTR mutations where progression of amyloid tissue deposition has been documented as the result of amyloid fibril formation from normal (wild-type) TTR. Although it is obvious that OLT has benefited many FAP patients, there remains a need for further therapies.",
keywords = "Amyloidosis, Familial amyloidotic polyneuropathy, FAP, Liver transplant, Transthyretin, TTR",
author = "Merrill Benson",
year = "2013",
month = "2",
doi = "10.1002/mus.23521",
language = "English",
volume = "47",
pages = "157--162",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Liver transplantation and transthyretin amyloidosis

AU - Benson, Merrill

PY - 2013/2

Y1 - 2013/2

N2 - Liver transplantation as a specific treatment of transthyretin amyloidosis was first performed in 1990. The rationale for this treatment was that removal of the source (liver) of the amyloid precursor protein (mutated transthyretin) would stop progression of the disease. Indeed, after orthotopic liver transplantation (OLT), mutant transthyretin (TTR) is rapidly cleared from circulation. In the last 20 years, >2000 familial amyloidotic polyneuropathy (FAP) patients have received liver transplants. For these patients, prospective monitoring has shown prolongation of life compared with FAP patients who have not undergone liver transplantation. The most favorable results have been for FAP patients with the Val30Met TTR mutation. Less favorable results have been seen for patients with other TTR mutations where progression of amyloid tissue deposition has been documented as the result of amyloid fibril formation from normal (wild-type) TTR. Although it is obvious that OLT has benefited many FAP patients, there remains a need for further therapies.

AB - Liver transplantation as a specific treatment of transthyretin amyloidosis was first performed in 1990. The rationale for this treatment was that removal of the source (liver) of the amyloid precursor protein (mutated transthyretin) would stop progression of the disease. Indeed, after orthotopic liver transplantation (OLT), mutant transthyretin (TTR) is rapidly cleared from circulation. In the last 20 years, >2000 familial amyloidotic polyneuropathy (FAP) patients have received liver transplants. For these patients, prospective monitoring has shown prolongation of life compared with FAP patients who have not undergone liver transplantation. The most favorable results have been for FAP patients with the Val30Met TTR mutation. Less favorable results have been seen for patients with other TTR mutations where progression of amyloid tissue deposition has been documented as the result of amyloid fibril formation from normal (wild-type) TTR. Although it is obvious that OLT has benefited many FAP patients, there remains a need for further therapies.

KW - Amyloidosis

KW - Familial amyloidotic polyneuropathy

KW - FAP

KW - Liver transplant

KW - Transthyretin

KW - TTR

UR - http://www.scopus.com/inward/record.url?scp=84873028718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873028718&partnerID=8YFLogxK

U2 - 10.1002/mus.23521

DO - 10.1002/mus.23521

M3 - Article

C2 - 23169427

AN - SCOPUS:84873028718

VL - 47

SP - 157

EP - 162

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 2

ER -